R-Pharm has filed an innovative COVID-19 medicine patent application

March 30

March 30, 2019 – R-Pharm Group has filed its first international patent application regarding biotech medicine that binds viral particles of COVID-19 and prevents them from penetrating alveolar cells.

“Research and development of this medicine is on early stages. Despite that, it is very important for us, so we decided to speed it up. We believe, that along with other promising drug candidates, this molecule is on its way to land a decisive strike against COVID-19 both in Russia and around the world”, stated R-Pharm’s chairman of the board Alexey Repik.

Group has launched a set of comprehensive measures aiming to curb COVID-19 pandemic. These measures range from development of new molecules and therapy methods to reevaluation of the current product portfolio.

Other company news

The interim analysis of randomized Phase III clinical trial of Coronavir (favipiravir) has been published  in the peer-reviewed scientific...
read more...
August 10
R-Pharm Group announces positive results of CREDO 2, a pivotal global (1648 patients in 18 countries) Phase III clinical study of IL-6...
read more...
July 2
R-Pharm Holding, LLC (Headquarters: Moscow, Russia; Chairman: Alexey Repik, hereinafter R-Pharm) and Canon Medical Systems Corporation...
read more...
June 22